Abstract：Objective To evaluate the clinical value of next-generation sequencing (NGS) in neonatal disease screening, particularly its advantages when combined with tandem mass spectrometry (MS/MS). Methods A prospective study was conducted involving blood samples from 1 999 neonates born at the Shenzhen Guangming District People's Hospital, between May and August 2021. All samples were initially screened using MS/MS and fluorescence immunoassay, followed by NGS to detect high-frequency variation sites in 135 related pathogenic genes. Suspected positive variants were validated using Sanger sequencing or multiplex ligation-dependent probe amplification in family studies. Results No confirmed positive cases were found in the MS/MS analysis of the 1 999 neonates. Genetic screening identified 58 positive cases (2.90%), 732 carriers of pathogenic genes (36.62%), and 1 209 negative cases (60.48%). One case of neonatal intrahepatic cholestasis was diagnosed (0.05%, 1/1 999). Fluorescence immunoassay identified 39 cases of glucose-6-phosphate dehydrogenase (G6PD) deficiency (1.95%, 39/1 999), while genetic screening identified 43 cases of G6PD deficiency (2.15%, 43/1 999). The fluorescence immunoassay also detected 6 cases of hyperthyrotropinemia (0.30%, 6/1 999), all of whom carried DUOX2 gene variants. The top ten pathogenic gene carrier rates were G6PD (12.8%), DUOX2 (8.7%), HBB (8.2%), ATP7B (6.6%), GJB2 (5.7%), SLC26A4 (5.6%), PAH (5.6%), ACADSB (4.6%), SLC25A13 (4.2%), and SLC22A5 (4.1%). Conclusions NGS can serve as an effective complement to MS/MS, significantly improving the detection rate of inherited metabolic disorders in neonates. When combined with family validation, it enables precise diagnosis, particularly demonstrating complementary advantages in screening for monogenic diseases such as G6PD deficiency.
JIANG Li-Hong,WU Ben-Qing,ZHAO Zheng-Yan. Clinical application of next-generation sequencing in early screening of neonatal diseases[J]. CJCP, 2025, 27(4): 432-437.
Gu X, Wang Z, Ye J, et al. Newborn screening in China: phenylketonuria, congenital hypothyroidism and expanded screening[J]. Ann Acad Med Singap, 2008, 37(12 Suppl): 104-107. PMID: 19904469.
Kemper AR, Green NS, Calonge N, et al. Decision-making process for conditions nominated to the recommended uniform screening panel: statement of the US Department of Health and Human Services Secretary's Advisory Committee on Heritable Disorders in Newborns and Children[J]. Genet Med, 2014, 16(2): 183-187. PMID: 23907646. DOI: 10.1038/gim.2013.98.
Fabie NAV, Pappas KB, Feldman GL. The current state of newborn screening in the United States[J]. Pediatr Clin North Am, 2019, 66(2): 369-386. PMID: 30819343. DOI: 10.1016/j.pcl.2018.12.007.
Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen)[J]. Genet Med, 2020, 22(2): 245-257. PMID: 31690835. PMCID: PMC7313390. DOI: 10.1038/s41436-019-0686-8.
Milko LV, Funke BH, Hershberger RE, et al. Development of Clinical Domain Working Groups for the Clinical Genome Resource (ClinGen): lessons learned and plans for the future[J]. Genet Med, 2019, 21(4): 987-993. PMID: 30181607. PMCID: PMC6401338. DOI: 10.1038/s41436-018-0267-2.
Tong F, Wang J, Xiao R, et al. Application of next generation sequencing in the screening of monogenic diseases in China, 2021: a consensus among Chinese newborn screening experts[J]. World J Pediatr, 2022, 18(4): 235-242. PMID: 35292922. DOI: 10.1007/s12519-022-00522-8.
Rehder C, Bean LJH, Bick D, et al. Next-generation sequencing for constitutional variants in the clinical laboratory, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG)[J]. Genet Med, 2021, 23(8): 1399-1415. PMID: 33927380. DOI: 10.1038/s41436-021-01139-4.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424. PMID: 25741868. PMCID: PMC4544753. DOI: 10.1038/gim.2015.30.
McCabe LL, Therrell BL, McCabe ER. Newborn screening: rationale for a comprehensive, fully integrated public health system[J]. Mol Genet Metab, 2002, 77(4): 267-273. PMID: 12468271. DOI: 10.1016/s1096-7192(02)00196-8.
Delado?y J, Ruel J, Giguère Y, et al. Is the incidence of congenital hypothyroidism really increasing? A 20-year retrospective population-based study in Québec[J]. J Clin Endocrinol Metab, 2011, 96(8): 2422-2429. PMID: 21632812. DOI: 10.1210/jc.2011-1073.
Matern D, Tortorelli S, Oglesbee D, et al. Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004-2007)[J]. J Inherit Metab Dis, 2007, 30(4): 585-592. PMID: 17643193. DOI: 10.1007/s10545-007-0691-y.
